Insmed, Inc.
Here’s whether Insmed, Inc. (INSM) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: strong 1-year return of +60.6%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-4.74% over 10 days); RSI 26 — oversold; 3-month momentum negative (-33.0%); rising volume on a downtrend (distribution, 1.40x avg). Currently 50.1% off its 52-week high. Score: -5/7.
INSM is trading below its 200-day MA ($155.99) — a key warning sign the longer-term trend is under pressure. An RSI of 26.5 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +60.6% compares to +27.9% for SPY (beat the market by 32.7%). The current 50.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.